Cargando…

Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients

INTRODUCTION: Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and havi...

Descripción completa

Detalles Bibliográficos
Autores principales: Assi, Hazem I., Alameh, Ibrahim A., Khoury, Jessica, Abdul Halim, Nour, El Karak, Fadi, Farhat, Fadi, Berro, Juliett, Sbaity, Eman, Charafeddine, Maya, Tfayli, Arafat, Salem, Ziad, El Saghir, Nagi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719508/
https://www.ncbi.nlm.nih.gov/pubmed/33312202
http://dx.doi.org/10.1155/2020/9238084
_version_ 1783619695723675648
author Assi, Hazem I.
Alameh, Ibrahim A.
Khoury, Jessica
Abdul Halim, Nour
El Karak, Fadi
Farhat, Fadi
Berro, Juliett
Sbaity, Eman
Charafeddine, Maya
Tfayli, Arafat
Salem, Ziad
El Saghir, Nagi
author_facet Assi, Hazem I.
Alameh, Ibrahim A.
Khoury, Jessica
Abdul Halim, Nour
El Karak, Fadi
Farhat, Fadi
Berro, Juliett
Sbaity, Eman
Charafeddine, Maya
Tfayli, Arafat
Salem, Ziad
El Saghir, Nagi
author_sort Assi, Hazem I.
collection PubMed
description INTRODUCTION: Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and having reliable prognostic factors could significantly improve rates of appropriate treatment administration. In this study, we showcase the impact of genomic tests on adjuvant treatment decisions in EBC patients. MATERIALS AND METHODS: This is a retrospective study that includes EBC patients treated between December 2016 and February 2018. The physician's choice of treatment was recorded before and after obtaining the results of the genomics tests. Baseline demographics and pathological data were collected from medical records. RESULTS: A total of 75 patients were included. Fifty patients underwent Oncotype DX genomic analysis, 11 patients underwent Prosigna analysis, and 14 patients underwent Endopredict analysis. A total of 21 physicians' plans (28%) were initially undecided and then carried out after obtaining genomic test results. 13 patients were planned to undergo endocrine therapy alone, while 8 were planned to undergo both endocrine therapy and chemotherapy. Treatment was changed in 26 patients (34.67%). The decision to deescalate therapy was taken in 19 patients (25.33%). The decision to escalate treatment was made in 7 patients (9.33%). CONCLUSION: Our study demonstrates the importance of genomics testing, as it assisted physicians in avoiding unnecessary adjuvant chemotherapy in 25.33% of patients, thus reducing side effects of chemotherapy and the financial burden on patients.
format Online
Article
Text
id pubmed-7719508
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-77195082020-12-11 Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients Assi, Hazem I. Alameh, Ibrahim A. Khoury, Jessica Abdul Halim, Nour El Karak, Fadi Farhat, Fadi Berro, Juliett Sbaity, Eman Charafeddine, Maya Tfayli, Arafat Salem, Ziad El Saghir, Nagi J Oncol Research Article INTRODUCTION: Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and having reliable prognostic factors could significantly improve rates of appropriate treatment administration. In this study, we showcase the impact of genomic tests on adjuvant treatment decisions in EBC patients. MATERIALS AND METHODS: This is a retrospective study that includes EBC patients treated between December 2016 and February 2018. The physician's choice of treatment was recorded before and after obtaining the results of the genomics tests. Baseline demographics and pathological data were collected from medical records. RESULTS: A total of 75 patients were included. Fifty patients underwent Oncotype DX genomic analysis, 11 patients underwent Prosigna analysis, and 14 patients underwent Endopredict analysis. A total of 21 physicians' plans (28%) were initially undecided and then carried out after obtaining genomic test results. 13 patients were planned to undergo endocrine therapy alone, while 8 were planned to undergo both endocrine therapy and chemotherapy. Treatment was changed in 26 patients (34.67%). The decision to deescalate therapy was taken in 19 patients (25.33%). The decision to escalate treatment was made in 7 patients (9.33%). CONCLUSION: Our study demonstrates the importance of genomics testing, as it assisted physicians in avoiding unnecessary adjuvant chemotherapy in 25.33% of patients, thus reducing side effects of chemotherapy and the financial burden on patients. Hindawi 2020-11-28 /pmc/articles/PMC7719508/ /pubmed/33312202 http://dx.doi.org/10.1155/2020/9238084 Text en Copyright © 2020 Hazem I. Assi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Assi, Hazem I.
Alameh, Ibrahim A.
Khoury, Jessica
Abdul Halim, Nour
El Karak, Fadi
Farhat, Fadi
Berro, Juliett
Sbaity, Eman
Charafeddine, Maya
Tfayli, Arafat
Salem, Ziad
El Saghir, Nagi
Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
title Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
title_full Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
title_fullStr Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
title_full_unstemmed Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
title_short Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
title_sort impact of commercialized genomic tests on adjuvant treatment decisions in early stage breast cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719508/
https://www.ncbi.nlm.nih.gov/pubmed/33312202
http://dx.doi.org/10.1155/2020/9238084
work_keys_str_mv AT assihazemi impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT alamehibrahima impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT khouryjessica impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT abdulhalimnour impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT elkarakfadi impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT farhatfadi impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT berrojuliett impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT sbaityeman impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT charafeddinemaya impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT tfayliarafat impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT salemziad impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients
AT elsaghirnagi impactofcommercializedgenomictestsonadjuvanttreatmentdecisionsinearlystagebreastcancerpatients